Pharma giant Merck expects Trump’s tariffs to cost the company $200 million

Quick Summary:

The news comes a week after J&J executives said they expect $400 million in tariff-induced expenses in 2025.

In an April 24 earnings call, executives said they expect $200 million in tariff-related costs in 2025.

Merck is also preparing for its blockbuster cancer drug Keytruda, which single-handedly accounts for more than 45% of the drugmaker’s global drug sales, to face patent expiration in 2028.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Maia Anderson, Healthcare Brew

Category: EconomyBusiness

Markets: United States

Topics: Tariffs Merck Pharmaceutical Industry Morning Brew Tariffs and trade

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-04-25 @ 18:13:55 (1 days ago)

News Timezone: GMT +8:00

News Source URL: fortune.com

Language: English

Article Length: 514 words

Reading Time: 3 minutes read

Sentences: 4 lines

Sentence Length: 129 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Fortune

News ID: 28210193

View Article Analysis

About Fortune

Main Topics: EconomyBusiness

Official Website: fortune.com

Update Frequency: 6 posts per day

Year Established: 1929

Headquarters: United States

News Last Updated: 9 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #95

Publisher Details

Frequently Asked Questions